1.
Delayed Lactogenesis II and potential utility of antenatal milk expression in women developing late-onset preeclampsia: a case series.
Demirci, J, Schmella, M, Glasser, M, Bodnar, L, Himes, KP
BMC pregnancy and childbirth. 2018;(1):68
Abstract
BACKGROUND Preeclampsia is a multi-system, hypertensive disorder of pregnancy that increases a woman's risk of later-life cardiovascular disease. Breastfeeding may counteract the negative cardiovascular sequela associated with preeclampsia; however, women who develop preeclampsia may be at-risk for suboptimal breastfeeding rates. In this case series, we present three cases of late-onset preeclampsia and one case of severe gestational hypertension that illustrate a potential association between hypertensive disorders of pregnancy and suboptimal breastfeeding outcomes, including delayed onset of lactogenesis II and in-hospital formula supplementation. CASE PRESENTATION All cases were drawn from an ongoing pilot randomized controlled trial investigating the impact of antenatal milk expression versus an education control on breastfeeding outcomes. All study participants were healthy nulliparous women recruited at 34-366/7 gestational weeks from a hospital-based midwife practice. The variability in clinical presentation among the four cases suggests that any effect of hypertensive disorders on breastfeeding outcomes is likely multifactorial in nature, and may include both primary (e.g., preeclampsia disease course itself) and secondary (e.g., magnesium sulfate therapy, delayed at-breast feeding due to maternal-infant separation) etiologies. We further describe the use of antenatal milk expression (AME), or milk expression and storage beginning around 37 weeks of gestation, as a potential intervention to mitigate suboptimal breastfeeding outcomes in women at risk for preeclampsia and other hypertensive disorders of pregnancy. CONCLUSIONS Additional research is needed to address incidence, etiology, and interventions, including AME, for breastfeeding issues among a larger sample of women who develop hypertensive disorders of pregnancy.
2.
[Management of pregnancy in patients with systemic lupus erythematosus].
Ugarte, A, Villar, I, Ruiz-Irastorza, G
Revista clinica espanola. 2012;(10):491-8
Abstract
Patients with systemic lupus erythematosus are exposed to a remarkably high number of maternal-fetal complications during pregnancy. Knowledge regarding the reciprocal influence between lupus and pregnancy is the starting point to assure that these patients are correctly monitored. It is also important to carry out comprehensive preconception evaluation to individually evaluate the risk of each patient. The immunological profile, history of nephritis, presence of chronic damage and disease activity are the basic data that will determine the specific individual risk profile. Finally, correct drug management must be assured during this period, based on the safety profile of the different treatments during pregnancy and lactation.
3.
Pregnancy complicated by obesity: midwifery management.
Jevitt, C
Journal of midwifery & women's health. 2009;(6):445-51
Abstract
Obesity-related comorbidities such as gestational diabetes and hypertension have the potential to affect at least 25% of women in the United States. Midwives have been caring for and collaboratively managing these conditions in nonobese women for decades. Prenatal weight gain advice should be based on pregravid body mass index and aim for the lower end of the 1990 Institute of Medicine prenatal weight gain ranges. Obese women may require extra ultrasound and blood glucose testing during pregnancy. Pregnancy complicated by obesity may limit the place and style of birth. Midwives can integrate management techniques into the perinatal care of women whose body mass indices exceed 29 to reduce risk and future disease for mothers and newborns.
4.
Maternal phenylketonuria syndrome and case management implications.
Gambol, PJ
Journal of pediatric nursing. 2007;(2):129-38
Abstract
Well-established dietary protocols have prevented mental retardation for infants born with phenylketonuria (PKU). Dietary protocols for managing females with PKU in their reproductive years exist but are not followed by most of them. Infants who are born to mothers with PKU who are not on dietary treatment usually have serious medical problems, such as mental retardation, heart defects, and other serious congenital anomalies (e.g., orofacial clefting and bladder exstrophy)--a condition known as maternal PKU syndrome. The focus of this article is to review the pathophysiology, associated developmental issues, and existing management protocols used to manage these two separate but highly connected disorders.